A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings

Mark Anderson(Rochester Institute of Technology), Michal Juraska(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Kagisho Baepanye(Infectious Disease Research Institute), Maurine D. Miner(Fred Hutch Cancer Center), Srilatha Edupuganti(Emory University), E. Shava, M.S. Cohen(Fundação Oswaldo Cruz), Nokuzola Dorcas Luthuli, Nidhi Kochar(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Simbarashe Takuva(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Christian Karg, Precious Garnett(Desmond Tutu HIV Foundation), Erika Rudnicki(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Pamela Mukwekwerere(University of Zimbabwe), Lawrence Corey(Fred Hutch Cancer Center), India Tindale(Infectious Disease Research Institute), Shelly Karuna(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Deborah Donnell(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), John R. Mascola(National Institute of Allergy and Infectious Diseases), Erica Lazarus(Norwegian Womens Public Health Association), J. Ledgerwood, P. Andrew(Family Health International 360), David Burns(Norwegian Womens Public Health Association), John Hural(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Ernest R. Greene(University of North Carolina at Chapel Hill), Nyaradzo Mgodi(University of Zimbabwe), the HVTN HPTN Team, Katherine L. Marshall
UNC Libraries
November 17, 2023
Cited by 0


Related Papers